Episode 30. Management of High-Risk Myeloma

Blood Cancer Talks

תוכן מסופק על ידי Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.

1y ago 1:08:29

MP3•בית הפרקים

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon:

1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:

https://pubmed.ncbi.nlm.nih.gov/37315268/

2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:

https://pubmed.ncbi.nlm.nih.gov/34092058/

3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):

https://pubmed.ncbi.nlm.nih.gov/32157174/

4. French data on adverse prognostic impact of del(1p32):

https://pubmed.ncbi.nlm.nih.gov/36375118/

5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):

https://pubmed.ncbi.nlm.nih.gov/33357482/

6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:

https://ashpublications.org/blood/article/140/Supplement%201/10144/488521

7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):

https://pubmed.ncbi.nlm.nih.gov/35731911/

8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:

https://pubmed.ncbi.nlm.nih.gov/34732857/

52 פרקים

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff